Changes in Hong Kong stocks | Baiosetu-B (02315) rose more than 5% in the intraday period. The company successfully landed on the Science and Technology Innovation Board to build an A+H dual-platform listing pattern

The Zhitong Finance App learned that Biosetu-B (02315) rose more than 5% in the intraday period. As of press release, it had risen 4.15% to HK$28.12, with a turnover of HK$19.5098 million.

According to news, on December 10, Baiosetu was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange. This is another key step in deepening the capital market layout and enhancing corporate value after landing on the Hong Kong Stock Exchange on September 1, 2022. It marks the company's successful construction of an “H+A” dual-platform listing pattern.

Western Securities released a research report stating that in March 2020, the company took the lead in launching the “Thousands of Antibodies” program. The “antibody shelf” model, on the one hand, saves development time and reduces uncertainty in early development. On the other hand, it is expected to help pharmaceutical companies improve R&D efficiency and success rate of clinical transformation by comparing multiple targets in parallel at the source. The company's antibody business began in 2020, with annual revenue of 41 million yuan, while revenue reached 163 million yuan in the first half of 2025, an increase of 37.8% over the previous year. As subsequent molecules advance clinically, the value of the company's platform is expected to expand further.